Anti-CD30 CAR T-cells(Josep Carreras Leukaemia Research Institute)(Anti-CD30 CAR T-cells(Josep Carreras Leukaemia Research Institute))

概要

基本信息

药物类型

自体CAR-T

别名

HSP-CAR30、HSP CAR30

靶点

CD30

作用方式

抑制剂

作用机制

CD30抑制剂(肿瘤坏死因子受体超家族成员8抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症-

非在研适应症

典型霍奇金淋巴瘤复发性T细胞淋巴瘤

原研机构

Josep Carreras Leukaemia Research Institute

在研机构-

非在研机构

Josep Carreras Leukaemia Research Institute

Instituto De SAlud Carlos Iii De Madrid

最高研发阶段无进展临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Anti-CD30 CAR T-cells(Josep Carreras Leukaemia Research Institute) 相关的临床试验

NCT04653649

/ Unknown status临床1/2期IIT

Immunotherapy With Autologous CAR30 T Cells for Patients With Classic Hodgkin Lymphoma and Non-Hodgkin T-cell Lymphoma With CD30 Expression.

HSP-CAR30 is a cell suspension of genetically modified T-cells to express a second generation (4-1BBz) chimeric antigen receptor (CAR) directed against CD30.
This is a phase I/IIa, interventional, single arm, open label, treatment study to evaluate the safety, tolerability and efficacy of HSP-CAR30 in patients with relapsed/refractory Hodgkin lymphoma and relapsed/refractory T-cell lymphoma expressing CD30.

开始日期2020-09-29

申办/合作机构

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

[+2]

100 项与 Anti-CD30 CAR T-cells(Josep Carreras Leukaemia Research Institute) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD30 CAR T-cells(Josep Carreras Leukaemia Research Institute) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD30 CAR T-cells(Josep Carreras Leukaemia Research Institute) 相关的专利（医药）

登录后查看更多信息

13

项与 Anti-CD30 CAR T-cells(Josep Carreras Leukaemia Research Institute) 相关的文献（医药）

2023-12-02·Expert review of hematology

Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma

Review

作者: Ma, Xiao Chen ; Lv, Xiao ; Li, Ying

INTRODUCTION:

After therapy, approximately 15% of individuals with Hodgkin's lymphoma (HL) develop relapsed or drug-resistant Hodgkin's lymphoma (r/rHL). r/rHL has a high fatality rate and poor therapeutic prognosis. CD30 CAR-T-cell therapy has emerged as a new way to treat r/rHL in recent years. However, CD30CAR-T cells are still being explored in clinical trials. To help more patients, this review focuses on current CD30CAR-T-cell advancements as well as clinical breakthroughs in treatment of r/rHL.

AREAS COVERED:

This research examines the mechanism of action of CD30 CAR-T cells, their function in the real-world therapy of r/rHL, and the influence of different treatment regimens on treatment results.

EXPERT OPINION:

There has been much research into CD30 CAR-T cells as a result of their successful use in treatment of r/rHL. This research has helped us to understand CD30 CAR-T-cell safety as well as the management options available before and after its administration to increase patient survival and reduce side effects.

2023-06-01·HEMATOLOGICAL ONCOLOGY

DUAL TARGETING OF HODGKIN’S LYMPHOMA BY ANTI‐CD30 CAR‐T CELLS CO‐TRANSDUCED WITH AN ANTI‐PDL1 COSTIMULATORY RECEPTOR TO OVERCOME THE IMMUNOSUPPRESSIVE MICROENVIRONMENT

Article

作者: Tiacci, E. ; Capurro, M. ; Erol, G. ; Marra, A. ; Martarelli, N. ; Gentili, M. ; Gobbi, M. ; Falini, B. ; Perriello, V. M.

2023-06-01·British journal of haematology

CD30 as a therapeutic target in adult haematological malignancies: Where are we now?

Review

作者: Veyri, M. ; Marcelin, A. G. ; Le Bras, F. ; Todesco, E. ; Spano, J. P.

CD30 is a transmembrane protein from the tumour necrosis factor receptor superfamily. It is expressed on a small subset of activated T and B lymphocytes, and various lymphoid neoplasms. CD30 is a particularly interesting treatment target because its levels are high in tumours but low in healthy tissues. Several therapeutic strategies targeting CD30 have been developed, including monoclonal antibodies, conjugated antibodies (combination of brentuximab vedotin with chemotherapy or immunotherapy), bispecific antibodies and cell and gene therapies, such as anti-CD30 CAR-T cells in particular. We briefly review the biology of CD30 which makes it a good therapeutic target, and we describe all of the anti-CD30 therapies that have emerged to date.

100 项与 Anti-CD30 CAR T-cells(Josep Carreras Leukaemia Research Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
典型霍奇金淋巴瘤	临床2期	西班牙	Josep Carreras Leukaemia Research Institute	2020-09-29
典型霍奇金淋巴瘤	临床2期	西班牙	Instituto De SAlud Carlos Iii De Madrid	2020-09-29
复发性T细胞淋巴瘤	临床2期	西班牙	Josep Carreras Leukaemia Research Institute	2020-09-29
复发性T细胞淋巴瘤	临床2期	西班牙	Instituto De SAlud Carlos Iii De Madrid	2020-09-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04653649 (ASH2024) 人工标引	临床1/2期	霍奇金淋巴瘤 \| CD30阳性T细胞淋巴瘤 TNFRSF8 Positive	27	HSP-CAR30+T cells 3x106/kg	簾顧簾鹽淵艱願簾鑰糧(選壓餘窪廠膚觸艱窪衊) = CRS in 39% of patients, 10 patients (91%) with grade 1, and 1 patient (9%) with grade 3. One patient had grade 3 ICANS that fully resolved with steroids and anakinra, and one had grade 1 macrophage activation syndrome. Self-limiting grade 1 skin rash was observed in 6 (21%) of patients. One patient with history of cytomegalovirus (CMV) infections developed CMV pneumonia, and one patient had pulmonary tuberculosis, both resolved. 網願製鹽鹽衊簾襯糧鹹 (獵構築顧網繭淵獵襯鏇 ) 更多	积极	2024-12-09